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Abstract 
Background: An identical homozygous missense variant in EIF3F, identified through a large‑scale genome‑wide 
sequencing approach, was reported as causative in nine individuals with a neurodevelopmental disorder, character‑
ized by variable intellectual disability, epilepsy, behavioral problems and sensorineural hearing‑loss. To refine the phe‑
notypic and molecular spectrum of EIF3F-related neurodevelopmental disorder, we examined independent patients.
Results: 21 patients were homozygous and one compound heterozygous for c.694T>G/p.(Phe232Val) in EIF3F. Hap‑
lotype analyses in 15 families suggested that c.694T>G/p.(Phe232Val) was a founder variant. All affected individuals 
had developmental delays including delayed speech development. About half of the affected individuals had behav‑
ioral problems, altered muscular tone, hearing loss, and short stature. Moreover, this study suggests that microceph‑
aly, reduced sensitivity to pain, cleft lip/palate, gastrointestinal symptoms and ophthalmological symptoms are part 
of the phenotypic spectrum. Minor dysmorphic features were observed, although neither the individuals’ facial nor 
general appearance were obviously distinctive. Symptoms in the compound heterozygous individual with an addi‑
tional truncating variant were at the severe end of the spectrum in regard to motor milestones, speech delay, organic 
problems and pre‑ and postnatal growth of body and head, suggesting some genotype–phenotype correlation.
Conclusions: Our study refines the phenotypic and expands the molecular spectrum of EIF3F‑related syndromic 
neurodevelopmental disorder.
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Introduction
Bi-allelic variants in the EIF3F gene have recently been 
published as the cause for a syndromic neurodevel-
opmental disorder (NDD) (OMIM #618,295: intellec-
tual developmental disorder, autosomal recessive 67). 
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Variants were identified by a large exome-wide reces-
sive burden analysis of > 4500 families with no previous 
molecular diagnosis [9]. All nine affected individuals 
from seven families carried the same homozygous EIF3F 
missense variant c.694T>G/p.(Phe232Val). Beside vari-
able intellectual disability (ID) in all individuals, epilepsy 
occurred in six, and behavioral problems or sensori-
neural hearing loss in three individuals, respectively [9]. 
Rarer malformations described in single individuals were 
bilateral cleft lip and palate, congenital lobar emphysema, 
anal stenosis and undescended testis. Neurological rarer 
symptoms included a high pain threshold, drop attacks, 
muscular hypoplasia; upon brain imaging, an arach-
noid cyst in the right cerebellar pontine angle, promi-
nent perivascular spaces and mild tonsillar ectopia were 
observed in single patients.
EIF3F encodes an essential subunit of the largest 
eukaryotic translation initiation factor eIF3 which binds 
to a highly specific group of mRNAs involved in cell 
proliferation and growth, including cell cycle control, 
differentiation and apoptosis [8, 10]. In  vitro studies of 
induced pluripotent stem cells (iPSC), gene-edited to be 
homozygous for the c.694T>G/ p.(Phe232Val) variant, 
demonstrated lower EIF3F protein levels and reduced 
proliferation rates [9]. Furthermore, both heterozygous 
and homozygous variants reduced translation rates in 
iPSC cells [9], suggesting a loss-of-function mechanism.
In the current study, we assembled a group of 21 pre-
viously unreported individuals with homozygosity or 
compound heterozygosity for the variant c.694T>G/ 
p.(Phe232Val). We refine the EIF3F-related phenotypic 
spectrum in this group and describe an additional, so far 
unreported disease-causing variant. Thus, we confirm 
EIF3F-deficiency as a relatively prevalent cause for auto-
somal-recessive NDD.
Methods
Editorial policies and ethical considerations
Individual genetic testing was performed either in diag-
nostic or research settings. The study was approved by 
the ethical committee of the Friedrich-Alexander-Uni-
versität Erlangen-Nürnberg, and by local institutional 
review boards of the contributing institutions where 
applicable.
Affected individuals
The study group was gathered through GeneMatcher 
[14], and internal collaborations, such as the correspond-
ing authors of [9]. Parents or the legal guardians gave 
written informed consent before enrollment. Investiga-
tions were conducted according to Declaration of Hel-
sinki principles.
Methods
A questionnaire filled out by the patient’s clinical team 
was used to collect detailed clinical characteristics of 
affected individuals with bi-allelic EIF3F variants. To 
normalize body measurements (height, weight and 
head circumference) to the corresponding age, the 
publicly available data-source “https ://www.pedz.de/” 
based on birth data by Voigt et  al. [17] and studies 
reported by Kromeyer-Hauschild et al. [7] for older age 
groups were used.
EIF3F variants were identified by sequencing of 
autism/ intellectual disability gene panels, whole exome 
sequencing (WES) or whole genome sequencing, per-
formed as a clinical test or within a research project as 
described previously [4, 12, 13], or by Sanger sequenc-
ing for co-segregation testing in core family members, 
as presented in Additional file  1: Table  S1 and Addi-
tional file 2: Fig. S1.
We used genotypes of 136 frequent SNPs (MAF > 5%) 
generated from internal WES data (1818 independent 
samples, affected individual and parents of P13 and 
one affected individual of P14) covering EIF3F and its 
flanking regions (chr11: 7,614,107–8,413,933 (hg19)). 
We defined haplotype blocks using the definition of the 
model “solid spine of linkage disequilibrium (LD)” in 
Haploview [2] and determined haplotypes at an individ-
ual basis using PHASE vs.2.1.1 [15] as described previ-
ously [5]. Within the LD block of EIF3F, five of seven 
common SNPs (rs79714374, rs12421289, rs12278319, 
rs7941782, rs4758267, rs12420464, rs56392532) were 
identified to be tagging SNPs for six different haplo-
types with frequencies between 3.5 and 53.4%. The 
set of seven SNP was used to assess the haplotypes in 
other affected individuals with the homozygous EIF3F 
missense variant and if available, their parents. Some 
redundantly tagged SNPs (rs79714374 and rs56392532) 
had a coverage of < 10 × in affected individuals of P2, 
P3, P6, P10, P12, P17 (Table  1), but due to very high 
linkage disequilibrium in 1818 WES, their genotypes 
could be tagged by rs12420464 and rs12421289, respec-
tively. Genotypes of rs12278319 in mother of P10 and 
of rs79714374 and rs12420464 in the affected indi-
vidual of P17 could be inferred in single individuals of 
P10, P17 due to available genotypes in other core family 
members, and the ones of two SNPs in P4 (rs79714374, 
rs12420464) could be deduced to one of the haplotypes 
identified in 1818 WES data. Due to insufficient cov-
erage of two SNPs (< 15x) in the affected individual of 
P16, the DNA was sequenced by Sanger for rs12278319 
and rs12420464.
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Results
We identified the same homozygous missense variant 
c.694T>G/ p.(Phe232Val) in EIF3F (NM_003754) in 21 
individuals from 16 families (Fig. 1). All tested parents 
were heterozygous carriers of the variant (parents of 
pedigree 16 (P16) were not available for testing). Paren-
tal consanguinity was reported in one of 16 families. An 
additional affected individual (P3) was compound het-
erozygous for the maternally inherited missense vari-
ant c.694T>G/ p.(Phe232Val) and a paternally inherited 
variant c.861dup/ p.(Gln288AlafsTer14). The latter 
variant was absent in the Genome Aggregation Data-
base (gnomAD) [6], and was predicted to result in a 
frameshift and subsequently either in mRNA decay or a 
truncated protein (length reduced by 20%, exon 6 of 8) 
with altered structure.
The female individual of family P2 had two molecular 
diagnoses. In addition to the homozygous EIF3F variant, 
she had a de novo frameshift variant in MECP2, impli-
cated in Rett syndrome (OMIM #312750). As symptoms 
in EIF3F-related NDD considerably overlap with those 
in Rett syndrome, we did not include this individual in 
the summary of clinical aspects (Table 2), but presented 
details in Additional file 1: Table S1.
Among the reported individuals were 15 females (14 
total when excluding the individual with Rett syndrome) 
and 7 males. Overall, history of pregnancies and deliver-
ies were largely uneventful, although oligohydramnios 
was noted in one pregnancy (P9), and perinatal asphyxia 
suspected in another case (P14). The average age at the 
time of the last physical examination was 12.1 ± 9.6 years 
(mean ± standard deviation), with a median of 8.5 years; 
four individuals had an age of > 18 years.
All affected individuals had developmental delays. Con-
sidering motor milestones, 33% of ascertained individuals 
(4/12) exhibited delays in unassisted sitting (> 10 months) 
and 70% of individuals (14/20) in independent walk-
ing (≥ 18 months, Additional file 1: Table S1). The single 
individual with compound heterozygous EIF3F variants 
(P3) did not walk independently at the age of 5  years, 
but crawled. 24% of individuals (5/21) had not developed 
speech at the last examination including the compound 
heterozygous individual, while speech abilities varied 
widely between few words and simplified, but usable lan-
guage in the remaining individuals.
Hearing loss was reported in 57% of affected indi-
viduals (12/21). More than half of the probands (12/21; 
57%) were observed to have behavioral problems such 
as obsessive compulsory disorder, social problems, anxi-
ety, autism, hyperactivity, attention deficit, aggressivity 
or pica. Muscular hypo- or hypertonia was also common 
and diagnosed in 48% of affected individuals (10/21). 
Notably, different ophthalmological findings were 
observed in up to 38% of affected individuals (8/21) and 
included hyper-/myopia (38%), strabismus (14%), nys-
tagmus (5%) and coloboma (5%). Brain imaging revealed 
nonspecific findings in five of 13 examined affected indi-
viduals (38%). Five of 21 individuals (24%) had sleeping 
problems. Epilepsy was diagnosed in 15% of individuals 
(3/20).
Regression of cognitive abilities was observed in three 
of 21 individuals at an age of 2.5 years (P11.1), 21 years 
(P4.1) and in adulthood (P14). Two of these lost their 
speech abilities, while the third developed mood swings 
and demanded more attention. P14 had a combination of 
meningioma and psychosis, and an additional individual 
(P16) was operated on a meningioma.
Two individuals were noted to have reduced pain sen-
sitivity. In one proband, muscle atrophy was noted, while 
in two of the ten individuals with altered muscular tone, 
a combination of truncal hypotonia and hypertonic 
extremities was diagnosed.
Short stature was observed in 40% of affected indi-
viduals at the last physical examination (Table  2, Addi-
tional file  1: Table  S1). Interestingly, four of the seven 
individuals with short stature at the last examination 
(with available data of body length at birth and at the last 
examination), had normal body length at birth. Micro-
cephaly was common at the last physical examination 
(6/19; 32%), and microcephaly (4/10; 40%) or normo-
cephaly (6/10; 60%) remained consistent between birth 
and the last measurement. Notably, the compound het-
erozygous individual of P3 was both short for age and 
microcephalic.
Five of the individuals (24%) had gastrointestinal prob-
lems which included gastro-esophageal reflux disease, 
difficulties to swallow, alternating constipation and diar-
rhea and neonatal feeding problems. Cleft lip and pal-
ate (P15), tetralogy of Fallot (P3) or combination (P5) of 
a groove of lip (considered a minor variant of cleft lip, 
Fig.  2c, d) and a nasal fistula (Fig.  2c) were observed in 
a single individual each. The compound heterozygous 
individual had gastrointestinal problems and a congenital 
heart defect.
More prevalent dysmorphic findings included a tubular 
and/ or narrow nose, a pointed nasal tip and anteverted 
nares. We also observed posteriorly rotated ears, short 
and/ or encased (= embedded by abundant skin) fin-
ger and toe nails (Fig.  2, Table  2). Also, palpebral fis-
sures were fairly even in all affected individuals (Fig. 2). 
A unilateral single palmar crease was noted in four indi-
viduals. Dysmorphic features were generally subtle and 
non-specific and were not considered a recognizable 
facial gestalt.
Two individuals had initially received targeted diag-
nostics for short stature or failure to thrive including a 
Page 4 of 9Hüffmeier et al. Orphanet J Rare Dis          (2021) 16:136 
gene panel for short stature and testing for Russel-Sil-
ver syndrome (OMIM #180860). The individual com-
pound heterozygous for EIF3F variants presented with 
intrauterine growth retardation. Most other genetic 
testing that was performed in affected individuals 
(Angelman syndrome, Fragile X-syndrome) overlapped 
those reported previously [9].
Heterozygous carriers were mainly asymptomatic. 
One father was reported to have epilepsy, and one 
mother migraines. Those overlapping symptoms are 
likely unrelated and of different etiology.
To test whether the missense variant arose once or 
recurrently, we performed haplotype analyses. This 
revealed that the EIF3F variant was on an identical 
haplotype (minimal 7.8  kb) in 15 affected individu-
als of all tested families, suggesting a founder variant 
(Table 1).
Discussion
Our study confirms a relevant role of EIF3F in syndromic 
NDD. We observed the same pathogenic homozygous 
missense variant c.694T>G/ p.(Phe232Val) in all but one 
affected individual. This variant represents the  7th most 
common EIF3F missense variant in gnomAD (0.07%) 
with highest frequencies in Ashkenazi Jewish (0.21%) 
and non-Finnish European individuals (0.12%) [6]. In 
line with its pathogenicity, no individual in gnomAD was 
reported to be homozygous for this variant, in contrast 
to five of the six more frequent variants. The haplotype 
analyses performed in this study add the finding that the 
variant most probably arose once on a single haplotype, 
indicating a founder variant.
EIF3F was previously reported to be one of few genes 
significantly enriched for bi-allelic genotypes in large 
cohorts of individuals with NDD, due to the shared vari-
ant c.694T>G/ p.(Phe232Val) in all affected individuals 
[9]. The frequency of heterozygous carriers in gnomAD, 
especially in Non-Finnish European and Askenazi Jew-
ish individuals, is higher than for most other autosomal 
recessive NDDs. For many of the other autosomal reces-
sive NDDs, only few or a handful of families have been 
reported [1, 11]. In those diseases, predominantly trun-
cating variants are causative. Therefore, an identical, 
rather frequent missense variant in EIF3F in almost all 
affected individuals is an uncommon finding in NDDs, 
particularly in a cohort with heterogeneous, ethnical and 
regional backgrounds. Particularly common pathogenic 
variants have been observed in certain other genetic dis-
eases: e.g. p.Phe508del variant in CFTR in cystic fibro-
sis in Europeans, population-specific variants in HFE in 
Table 1 Haplotypes at EIF3F in 15 families
For haplotype analyses, seven intragenic SNPs were used: rs79714374, rs12421289, rs12278319, rs7941782, rs4758267, rs12420464 and rs56392532. Haplotype C–C-
A-C–C-G-C harboring the missense variant, had a frequency of 3.5% in 1818 independent, house-internal control WES from Germany. Genotypes of rs79714374 and 
rs56392532 in [brackets] had a low coverage, but due to very high linkage disequilibrium, their genotypes in individuals of P2, P3, P6, P10, P12, P17 could be tagged 
by rs12420464 and rs12421289, respectively. Genotypes in {other brackets} could be inferred in single individuals of P10, P17 due to available genotypes in other core 
family members and the ones in lowercase in [brackets] in P4 from haplotypes in 1818 control WES
P, pedigree; n.a, not applicable
§ c.861dup/ p.(Gln288AlafsTer14) is on the underlined haplotype in P3 (frequency of 0.158 in controls)
Pedigree Combination of haplotypes in…
…Affected individual …Mother (frequency of 2nd 
haplotype)
…Father (frequency of 2nd 
haplotype)
P1 CCA CCG C/CCA CCG C CCA CCG C/CCA CTG C (0.534) CCA CCG C/CTG CTG T (0.124)
P2 [C]CAC CGC /[C]CAC CGC [C]CAC CGC /[C]CAC TGC (0.534) [C]CAC CGC /[C]CGA CGC (0.158)
P3 [C]CAC CGC /[C]CGA CGC § [C]CACCG[C]/[C]CACTG[C] (0.534) [C]CGACG[C]§/[C]CACTG[C] (0.534)
P4 [c]CACC[g]C/[c]CACC[g]C [c]CACC[g]C/[c]CGCC[c]C (0.095) [c]CACC[g]C/[c]CACT[g]C (0.534)
P6 CCA CCG C/CCA CCG C [C]CAC CGC /[C]CGC CGC (0.095) [C]CACCG[C]/[C]CGACG[C] (0.158)
P7 CCA CCG C/CCA CCG C CCA CCG C/CTG CTG T (0.124) CCA CCG C/CCA CCG C (0.035)
P9 CCA CCG C/CCA CCG C CCA CCG C/CCA CTG C (0.534) CCA CCG C/CCG CCG C (0.095)
P10 [C]CAC CGC /[C]CAC CGC [C]CCCG[C]/[C]C[x]CTG[C] (n.a.) [C]CACCG[C]/[C]CACTG[C] (0.534)
P11 CCA CCG C/CCA CCG C CCA CCG C/CCA CTG C (0.534) CCACC[G]C/CCACT[G]C (0.534)
P12 [C]CAC CGC /[C]CAC CGC CCA CCG C/TTG CTT T (0.047) [C]CAC CGC /[C]CAC TGC (0.534)
P13 CCA CCG C/CCA CCG C CCA CCG C/CCG CCG C (0.095) CCA CCG C/CCA CTG C (0.534)
P14 CCA CCG C/CCA CCG C No WES No WES
P15 CCA CCG C/CCA CCG C No WES No WES
P16 CCA CCG C/CCA CCG C No WES No WES
P17 {C}CACC{G}C/{C}CACC{G}C CCACC[G]C/CTGCT[G]T (0.124) CCA CCG C/CCA CTG C (0.534)
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Table 2 Clinical features of individuals with bi‑allelic EIF3F variants
Feature Current study (total no. of indiv. with data; percent of 
aff. indiv.)
Published study (total no. of indiv. with data; 
percent of aff. indiv.) [9]
Homozygous for c.694T>G/ p.(Phe232Val) 16 (17; 94%) 9 (9; 100%)
Parental consanguinity 1 (17; 6%) 0 (7; 0%)
Family history
 Affected sibling(s) (bi‑allelic EIF3F variants) 4 (17; 24%) 2 (9; 22%)
 Parents with neurological symptoms 2 parents (34; 6%; epilepsy or migraines) 1 parent (14; 7%; mild ID)
Gender
 Female 15 (68%) 5 (56%)
 Male 7 (32%) 4 (44%)
Average age at last examination in years (median) 12.1 ± 9.6 (8.5) 16.3 ± 13.4 (13.0)
Pregnancy/delivery
 Eventful pregnancy 1 (21; 5%; oligo‑hydramnios) 1 (9; 11%; abnormal prenatal scan)
 Premature delivery 2 (20; 10%) 0 (9; 0%)
 Perinatal asphyxia 1 (19; 5%; suspected) 0 (9; 0%)
Development
 Global developmental delay 21 (21; 100%) 9 (9, 100%)
 Speech delay 21 (21; 100%) n.a
 No speech 5 (21; 24%) n.a
 Regression 3 (21; 14%) n.a
Behavioral problems 12 (21; 57%) 6 (9; 33%)
Hearing loss 12 (21; 57%) 3 (9; 33%)
Muscular hypo‑/hypertonia 10 (21; 48%) (%)
Ophthalmological findings
 Hyper‑/myopia 8 (21; 38%)
 Strabismus 3 (21; 14%) 1 (9; 11%)
 Nystagmus 1 (21; 5%)
 Coloboma 1 (21; 5%)
Brain imaging
 Nonspecific findings 5 (13; 38%) 3 (7; 43%)
Sleeping problems 5 (21; 24%) n.a
Epilepsy—confirmed 3 (20; 15%) 6 (7; 86%)
Other neurological issues
 Encephalopathy 1 (21; 5%) n.a
 Meningioma 2 (21; 10%)
 Psychosis 1 (21; 5%)
Body measurements
 Microcephaly at birth 4 (10; 40%) 0 (1; 0%)
 Short stature at birth 3 (15; 20%) n.a
 Microcephaly later 6 (19; 32%) 1 (8; 13%)
 Short stature later 8 (20; 40%) 1 (4; 25%)
Malformations
 Cleft lip/ palate (incl. minor form) 2 (20; 10%) 1 (9; 11%)
Gastrointestinal symptoms 5 (21; 24%) n.a
Dysmorphisms
 Fine facial features 2 (19; 11%) n.a
 Findings of nose 5 (20; 25%)
 Posteriorly rotated ears 7 (20; 35%)
 Deep set or encased nails of fingers and/ or toes 6 (20; 30%) n.a
 Abnormality 5th finger/ toe (shortness, clinodactyly) 3 (20; 15%)
 Short hands/ feet or slender fingers/ toes 5 (20; 25%)
 Flat feet 3 (20; 15%)
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hemochromatosis, and population-specific truncating 
variants in GJB2 in deafness. In this study, the EIF3F mis-
sense variant was identified in affected individuals of a 
wide spectrum of European/ West Asian origins includ-
ing French, English, Irish, Scottish, German, Bulgarian, 
Ukranian, Russian, Ashkenazi Jewish, and Iraqi. Hap-
lotype analyses support a single mutational event on a 
founder haplotype, while the nascence of the missense 
variant cannot be determined to a more localized region.
As only the identical missense variant in EIF3F has 
been functionally characterized and shown to result 
in reduced protein amount/ stability, decreased prolif-
eration rate and reduced translational rate, it remains 
speculative whether other missense variants might have 
comparable effects. Other rare missense variants might 
be functionally irrelevant or less harmful, as they might 
reach a certain harmful threshold causing NDD as in case 
of c.694T>G/ p.(Phe232Val) [9]. In contrast, the find-
ing of the rather severe phenotype in the individual with 
compound heterozygous variants in EIF3F suggests some 
genotype–phenotype correlation and a possibly residual 
EIF3F function in individuals homozygous for c.694T>G/ 
p.(Phe232Val). Of note, the overall number of truncating 
alleles in individuals in gnomAD v2.1.1 is extremely low 
(probability of being loss-of-function intolerant = 0.97, 
observed over expected variants = 0.07). Regarding lack 
of individuals with two truncating variants and of further 
affected individuals who are compound heterozygous for 
truncating variants, one might speculate that truncating 
variants on both alleles might not be compatible with life.
In this study, all affected individuals had global devel-
opmental delay of variable degree. Motor developmen-
tal delay was variable: one patient did not learn to walk 
independently, while most individuals learned walking 
late, and some individuals achieved motor milestones at 
a normal age. Similarly, the degree of ID varied widely. 
This study adds the finding of significant speech delay to 
the phenotype: the majority of individuals spoke more 
than few words, while a quarter of affected individuals 
had no speech development. In comparison to the initial 
report [9], hearing loss and behavioral difficulties were 
more common findings, and epilepsy less frequent in 
this study. Other frequent, so far unreported symptoms 
observed in this study are muscular hypotonia and/ or 
hypertonia, ophthalmologic findings and sleeping prob-
lems. Results of a murine study might indicate some 
Fig. 1 Pedigrees of 17 families with EIF3F‑related NDD. All parents, but the ones of P16 were identified as heterozygous carriers of EIF3F variants. P3 
is the family with the compound heterozygous individual. P, pedigree. †Individual with an additional, de novo MECP2 variant. DD, developmental 
delay; P, pedigree
Table 2 (continued)
Each row indicates the number of individuals/ families with the specified feature (number in parantheses indicate number of individuals with available information 
on this feature and percentage). Due to an additional confounding diagnosis of MECP2-related disorder in affected individual of P2 and the issue of overlapping 
phenotypes, we considered this individual only for the first four categories, but no further aspects
aff. indiv.: affected individuals; incl.: including; n.a. not applicable; No./ no.: number
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concordance with the human phenotype and support 
loss-of-function as the underlying cause: partial depletion 
of murine eIF3f amplified muscle atrophy compared to 
wild-type mice and reduced the MTOR pathway activa-
tion [3]. In regard to this study’s ophthalmologic findings, 
some of these (hyper-/ myopia) might not necessarily be 
related to EIF3F deficiency, as they are common in the 
general population.
The observation of reduced pain sensitivity in this study 
supports an association with this previously described, 
however rare symptom [9], as did the finding of muscular 
atrophy/ muscular hypoplasia in another individual. In 
concordance with the previous study, brain imaging did 
not reveal specific findings and were therefore not con-
sidered diagnostically indicative in EIF3F related NDD. 
Thus, genome-wide sequencing approaches (genome or 
exome sequencing) represent an essential component of 
the diagnostic work-up.
Developmental regression or neurodegeneration at 
various ages (2.5 to ~ 30 years) was observed in three of 
the 20 affected individuals which might be relevant for 
prognosis. However, two of the three individuals had 
additional diagnoses that are not necessarily related to 
this syndromic disorder: encephalopathy in an individual 
with vitamin B12 deficiency and psychosis in an individ-
ual with meningioma. In another individual, an increased 
seizure frequency also led to the diagnosis of meningi-
oma. The cohort size and the relatively young ages of the 
majority of individuals did not allow conclusions as to 
whether those symptoms are part of the disease spectrum 
or might have an independent cause. In large collections 
of malignancies (COSMIC; accessed on  3rd of December 
2020 at cancer.sanger.ac.uk), somatic EIF3F variants have 
been detected in 0.9% of 38,579 samples (n = 353) and 
did not include 130 meningioma samples, providing no 
further evidence for a role of EIF3F in tumorigenesis of 
meningioma [16].
Short stature, also occurring until adulthood, was com-
monly observed in this study group. Microcephaly was 
less frequent than short stature and of variable degree 
within this cohort, while longitudinal data indicated that 
head growth had a more constant course along the cen-
tiles than height.
Rare features that might be part of the EIF3F related 
NDD include functional problems of the gastrointesti-
nal tract, undescended testes, cleft lip and palate, heart 
defect and nasal fistula. Of those, the latter two had not 
been previously described. In agreement with the previ-
ous study, we did not recognize an obvious distinctive 
facial appearance. While the previous study had indicated 
tapered fingers and dysplastic toe nails [9], we observed 
nasal findings (tubular nose, pointed nasal tip, anteverted 
nares), posteriorly rotated ears as well as short and/ or 
encased finger and toe nails as more frequent, recurrent 
features.
In summary, this study confirms the previously 
reported EIF3F missense variant as a relatively frequent 
Fig. 2 Frontal and lateral facial profiles of six affected individuals carrying bi‑allelic EIF3F variants. a, b represent P3 at 5y, c P5 at 4m and d, e P5 at 
4y 3m, f, g show P9 at 13y and at 17y, respectively, h, i P12 at 2y 8m, j, k P13 at 3y 2m and l, m P15 at 6y 8m. All affected individuals have fairly even 
palpebral fissures, a pointed nasal tip which is rather prominent for age at lateral view. Note nasal fistula and groove at left lip in P5 before surgery 
(c), and after correction (d). y = years; m = months 
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cause of autosomal-recessive NDD. Characteristic 
features include global developmental delay, delayed 
speech development, behavioral difficulties, altered 
muscular tone, hearing loss, ophthalmological symp-
toms, short stature, and minor anomalies of the ears, 
nose, hands and feet.
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